NCT00006436View on ClinicalTrials.gov

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

January 29, 2001

Primary Completion Date

November 30, 2020

Study Completion Date

January 18, 2024

Conditions
Lymphoma, AIDS-relatedLymphoma, Large B-Cell, Diffuse
Interventions
BIOLOGICAL

Rituximab

2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5

BIOLOGICAL

Filgrastim

Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle

DRUG

EPOCH

combination chemotheray: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00006436 - EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection | Biotech Hunter | Biotech Hunter